Sara Huerta‐Yépez

Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis.

Ali R. Jazirehi, Sara Huerta‐Yépez, Genhong Cheng et al. · PubMed · 2005 · 178 citations

Apoptosis, Immunology, Cell Death +16

Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-κB and inhibition of Bcl-xL expression

Sara Huerta‐Yépez, Mario I. Vega, Ali R. Jazirehi et al. · Oncogene · 2004 · 164 citations

Trail-mediated Apoptosis, Nitric Oxide, Medicine +11

Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1

Stavroula Baritaki, Sara Huerta‐Yépez, Toshiyuki Sakai et al. · Molecular Cancer Therapeutics · 2007 · 145 citations · Full text

Rituximab (Chimeric Anti-CD20 Monoclonal Antibody) Inhibits the Constitutive Nuclear Factor-κB Signaling Pathway in Non-Hodgkin's Lymphoma B-Cell Lines: Role in Sensitization to Chemotherapeutic Drug-induced Apoptosis

Ali R. Jazirehi, Sara Huerta‐Yépez, Genhong Cheng et al. · Cancer Research · 2005 · 142 citations · Full text

Apoptosis, Immune Regulation, Immunology +21

Rituximab-Induced Inhibition of YY1 and Bcl-xL Expression in Ramos Non-Hodgkin’s Lymphoma Cell Line via Inhibition of NF-κB Activity: Role of YY1 and Bcl-xL in Fas Resistance and Chemoresistance, Respectively

Mario I. Vega, Ali R. Jazirehi, Sara Huerta‐Yépez et al. · The Journal of Immunology · 2005 · 127 citations · Full text